Condition: Hepatocellular Carcinoma · Sponsor: Anhui Provincial Hospital
This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.
This description comes directly from the study's public registry record.
Lianxin Liu · +86 18096656677 · liulx@ustc.edu.cn
Ji-Zhou Wang · +86 13836135864 · wangjoe@ustc.edu.cn
Always discuss trial participation with your own doctor first.
| No.2 People's Hospital of Fuyang city | Fuyang, Anhui, China | Recruiting |
| Anhui province hospital | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06498622